Vaccinex (VCNX)
(Delayed Data from NSDQ)
$4.49 USD
-0.26 (-5.47%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $4.37 -0.12 (-2.67%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Vaccinex, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 1 | 1 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 1 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 23 | 20 | 23 | 29 | 32 |
Income After Depreciation & Amortization | -23 | -20 | -22 | -28 | -32 |
Non-Operating Income | 3 | 0 | 1 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 0 | 0 |
Pretax Income | -20 | -20 | -22 | -29 | -32 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -20 | -20 | -22 | -29 | -32 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -20 | -20 | -22 | -29 | -32 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -20 | -22 | -28 | -32 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -23 | -20 | -22 | -28 | -32 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.46 | 0.20 | 0.14 | NA | 0.06 |
Diluted EPS Before Non-Recurring Items | -43.68 | -98.69 | -163.78 | NA | -518.65 |
Diluted Net EPS (GAAP) | -43.68 | -98.69 | -163.78 | -323.37 | -518.65 |
Fiscal Year end for Vaccinex, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.23 | 0.10 | 0.00 | 0.02 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.23 | 0.10 | 0.00 | 0.02 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.95 | 5.18 | 4.99 | 5.86 | 7.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.72 | -5.08 | -4.99 | -5.84 | -7.08 |
Non-Operating Income | 0.09 | 1.18 | 1.67 | 0.92 | 0.02 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.63 | -3.90 | -3.32 | -4.91 | -7.06 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.63 | -3.90 | -3.32 | -4.91 | -7.06 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.63 | -3.90 | -3.32 | -4.91 | -7.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.82 | 1.33 | 0.08 | 0.32 | 0.29 |
Diluted EPS Before Non-Recurring Items | -3.10 | -2.94 | -39.40 | -15.27 | -25.20 |
Diluted Net EPS (GAAP) | -3.10 | -2.94 | 17.78 | -15.27 | -25.20 |